Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.

TSXV:ARCH - Post by User

Arch Biopartners Inc > ARCH BIOPARTNERS 2021 -MY DUE DILLIGENCE- PHASE II COMPLETE

<< Previous

Bullboard Posts

Next >>

Post by Riverfolkon May 18, 2021 5:33pm

175 Views

Post# 33224346

ARCH BIOPARTNERS 2021 -MY DUE DILLIGENCE- PHASE II COMPLETE

Here is the science published by a world renounced third party:

Dipeptidase-1 ( Metablok)

Here is the technology developer and CSO explaining Metablok on a webinar:

Metablok Webinar

Here is the link for the Method of use Patent:

Metablok Patent

https://www.archbiopartners.com/index.php/investor-hub/fundamentals/press-releases-live/154-arch-biopartners-discloses-new-patent-filing-for-novel-drug-candidates-to-prevent-lung-inflammation

https://www.archbiopartners.com/index.php/investor-hub/fundamentals/press-releases-live/32-press-releases-2019/144-arch-biopartners-announces-issuance-of-us-patent-for-dipeptidase-1-inhibitor-drug-for-use-in-acute-kidney-injury

Here is the market potential for the kidney alone:

Currently, no specific therapies exist to prevent AKI in the world today. Management of AKI is supportive and includes life-sustaining therapy with dialysis. Patients that experience AKI are at high risk of developing chronic kidney disease, adverse cardiovascular outcomes and death.The worldwide market for AKI is estimated to be over $20 billion USD per year. ($325.4 dollars a share)

Currently the market cap is 76.2 million ($1.24)

Acute Kidney Injury

Here is the scientific community endorsement:

The Government of Canada Funded Arch for the Phase II trial after recommendations of the countries top scientists.

https://bc.ctvnews.ca/video?clipId=2101344

Prime Minister Of Canada Announcement - Arch Biopartners

Here is the expanding of the Phase II trial in Canada, Turkey and The USA:

Turkish Ministry Of Health

Health Canada Protocol

Additional Canadian Hospital

Here is the final dosing with 65 patients enrolled:

65 enrolled , 61 dosed

Here is the Clinical Trials Link:

https://clinicaltrials.gov/ct2/show/NCT04402957

Here is the link to Sedar:

No warrants outstanding

The Company has 61,462,302 common shares outstanding.

The Company expects to announce results in July 2021.

This is not investing advice, Sharing my due dilligence

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing